Horizon Pharma plc receives FDA fast track designation for ACTIMMUNE® in the treatment of friedreich’s ataxia
A new drug, ACTIMMUNE® (interferon gamma-1b) has been designated fast track status by the U.S Food and Drug Administration, which could make it available sooner.
Posted: 10/04/2015
The international ataxia research conference 2015 hailed a great success!
The IARC 2015 covered a range of research areas from new developments in genetics to clinical trials, with representatives from several pharmaceutical agencies and researchers from all four corners of the world in attendance.
Posted: 03/04/2015
